BC Cancer Protocol Summary for Symptomatic Management of Functional Carcinoid and Neuroendocrine Tumors of the GI Tract Using Lanreotide (SOMATULINE AUTOGEL)

Protocol Code *UGILAN*

Tumour Group *Gastrointestinal*

Contact Physician *GI Systemic Therapy*

ELIGIBILITY:

- Functional neuroendocrine tumors of the mid-gut or pancreas (including carcinoid tumors and VIPoma), with symptoms due to ectopic hormone secretion (flushes, diarrhea, wheezing, etc.)
- A BC Cancer Compassionate Access Program (CAP) request with appropriate clinical information for each patient must be approved prior to treatment. **CAP approval is valid as long as patient has symptomatic benefits.**

EXCLUSIONS:

- Pregnant or lactating women
- Hypersensitivity to lanreotide, somatostatin, or related peptides (such as octreotide)
- Complicated, untreated lithiasis of the bile ducts

TESTS:

- Pretreatment ultrasound of the gall bladder is recommended to rule out the formation of gallstones. Repeat periodically or if symptoms suggestive of biliary colic occur while on therapy.
- Blood glucose is recommended prior to therapy initiation and with dose changes.
- Cardiac monitoring (such as heart rate) is recommended in patients with pre-existing cardiac disorders.

PREMEDICATIONS:

- Not usually required

TREATMENT:

Drug	Dose	BC Cancer Administration Guideline
lanreotide (SOMATULINE AUTOGEL)	120 mg**	Deep Subcutaneous Injection (upper outer quadrant of buttocks alternating between right and left sides*)

*May use upper outer thigh for self-administration

Repeat every four weeks.

DOSE MODIFICATIONS:

Hepatic Dysfunction: Has not been studied in this patient population. Other patient populations (acromegaly) have safely used a dose of 60 mg in moderate or severe hepatic impairment.

Renal Dysfunction: No dose modification required for mild to moderate renal impairment. For severe renal impairment (CrCl less than 30 mL/min), it has not been studied in this patient population. Other patient populations (acromegaly) have safely used a dose of 60 mg.

PRECAUTIONS:

1. **Loss of blood glucose control** can occur: either hypoglycemia or hyperglycemia. Monitor blood glucose when treatment is initiated and when dose is changed. Diabetics may need their treatments adjusted. Insulin requirements may be reduced in insulin-dependent patients.
2. **Reduced gall bladder motility** may occur and may lead to formation of gall stones**.**
3. **Potential for some impairment in thyroid function:** monitor for signs and symptoms of hypothyroidism.
4. **Bradycardia** may occur in patients with or without existing cardiac disorders. Monitor heart rate. Initiate with caution in patients with pre-existing bradycardia.

Call the GI Systemic Therapy physician in your regional cancer centre or the GI Systemic Therapy Chair Dr. Janine Davies at (604) 877-6000 or 1-800-663-3333 with any problems or questions regarding this treatment program.

REFERENCES:

1. SOMATULINE® AUTOGEL Product Monograph Ipsen Biopharm Limited (EMD Serono Canada) Jan 30, 2015
2. SOMATULINE® AUTOGEL Product Monograph Ipsen Biopharm Limited NJ, USA Dec 2014
3. Lanreotide monograph. Cancer Drug Manual. BC Cancer Agency. Vancouver BC: January 2010